My watch list
my.bionity.com  
Login  

Alligator Bioscience to Receive USD 6 Million Milestone Payment from Janssen

08-Jan-2018

Alligator Bioscience announced that a development milestone payment of USD 6 million has been triggered under the partnership agreement for ADC-1013 (JNJ-64457107) with Janssen Biotech, Inc.

The milestone payment is for the partnership agreement to initiate a clinical combination study of ADC-1013 with one of Janssen's proprietary PD-1 inhibitors. This is the first out of a number of pre-defined milestones, related to the start of combination or phase II studies as part of the ADC-1013 clinical program, which all together have an aggregated potential value of 35 MUSD.

The licensing agreement with Janssen Biotech Inc. encompasses milestone payments up to a potential total value of USD 695 million.  Alligator is also eligible to receive tiered royalties on worldwide net sales upon successful launch and commercialization of ADC-1013.

"We are pleased that our collaboration with Janssen is continuing to progress according to plan", said Per Norlén, CEO at Alligator Bioscience. "The upcoming combination is a very important step in the continued clinical development. Synergy between ADC-1013 and PD-1 blocking antibodies is supported by pre-clinical data. If this translates to the clinic, it could create new treatment opportunities for many cancer patients".

Alligator's partner Janssen Biotech, Inc. is performing a phase I dose-escalation clinical study (ClinicalTrials: NCT02829099) with intravenous administration of JNJ-64457107 (ADC-1013). This study is ongoing with approximately 50 patients recruited to date.

Facts, background information, dossiers
  • Janssen Biotech
  • Alligator Bioscience
  • milestone payments
More about Alligator Bioscience
More about Janssen
  • News

    MorphoSys Sues Janssen Biotech and Genmab for Patent Infringement

    MorphoSys AG announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Janssen Biotech, and Genmab, A/S for patent infringement of U.S. Patent Number 8,263,746. This patent, which is owned by MorphoSys, describes and claims antibodies with particular f ... more

    Genmab achieves USD 45 million milestone

    Genmab A/S announced it has achieved a USD 45 million milestone in its DARZALEX™ (daratumumab) collaboration with Janssen Biotech, Inc. The milestone payment was triggered by the first commercial sale of DARZALEX in the United States. "Today marks a significant moment in the history of Genm ... more

    Genmab Reaches USD 10 Million Milestone in Daratumumab Collaboration with Janssen

    Genmab A/S announced it has reached the fourth milestone in its daratumumab collaboration with Janssen Biotech, Inc.. The USD 10 million milestone payment was triggered by progress in the ongoing Phase III study (“CASTOR” MMY3004) of daratumumab in combination with bortezomib and dexamethas ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE